What is the current valuation of the US purpura treatment market as of 2024?

The market valuation was $278.56 Million in 2024. Read More

What is the projected market size for the US purpura treatment market by 2035?

The market is projected to reach $592.06 Million by 2035. Read More

What is the expected CAGR for the US purpura treatment market during the forecast period 2025 - 2035?

The expected CAGR is 7.09% during the forecast period 2025 - 2035. Read More

Which treatment type had the highest valuation in the US purpura treatment market in 2024?

Corticosteroids had the highest valuation, ranging from $70.0 Million to $150.0 Million. Read More

What are the key players in the US purpura treatment market?

Key players include Bristol-Myers Squibb, Amgen, Roche, Novartis, Pfizer, Sanofi, Takeda, and GSK. Read More

How does the market valuation for adult patients compare to pediatric and geriatric patients in 2024?

The adult segment was valued between $150.0 Million and $320.0 Million, significantly higher than pediatric and geriatric segments. Read More

What is the valuation range for intravenous immunoglobulin treatment in the US purpura treatment market?

Intravenous immunoglobulin treatment was valued between $60.0 Million and $130.0 Million. Read More

Which disease type is expected to dominate the US purpura treatment market by 2035?

Immune thrombocytopenic purpura is expected to dominate, with a valuation range of $111.42 Million to $239.06 Million. Read More

What administration route is projected to have the highest valuation in the US purpura treatment market by 2035?

The oral administration route is projected to have the highest valuation, ranging from $111.48 Million to $239.56 Million. Read More

What is the valuation range for geriatric patients in the US purpura treatment market as of 2024?

The geriatric segment was valued between $78.56 Million and $162.06 Million in 2024. Read More

US Purpura treatment Market

ID: MRFR/Pharma/16773-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Purpura Treatment Market Research Report By Treatment Type (Corticosteroids, Intravenous Immunoglobulin, Platelet Transfusion, Desmopressin, Immunosuppressants), By Patient Type (Pediatric, Adult, Geriatric), By Disease Type (Immune Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Apparent Benign Purpura) and By Administration Route (Intravenous, Oral, Subcutaneous) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Treatment Type (USD Million)
  1. 4.1.1 Corticosteroids
  2. 4.1.2 Intravenous Immunoglobulin
  3. 4.1.3 Platelet Transfusion
  4. 4.1.4 Desmopressin
  5. 4.1.5 Immunosuppressants
2. 4.2 Chemicals and Materials, BY Patient Type (USD Million)
  1. 4.2.1 Pediatric
  2. 4.2.2 Adult
  3. 4.2.3 Geriatric
3. 4.3 Chemicals and Materials, BY Disease Type (USD Million)
  1. 4.3.1 Immune Thrombocytopenic Purpura
  2. 4.3.2 Thrombotic Thrombocytopenic Purpura
  3. 4.3.3 Apparent Benign Purpura
4. 4.4 Chemicals and Materials, BY Administration Route (USD Million)
  1. 4.4.1 Intravenous
  2. 4.4.2 Oral
  3. 4.4.3 Subcutaneous
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Takeda (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GSK (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY PATIENT TYPE
4. 6.4 US MARKET ANALYSIS BY DISEASE TYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY PATIENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DISEASE TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Treatment Type (USD Million, 2025-2035)

Corticosteroids
Intravenous Immunoglobulin
Platelet Transfusion
Desmopressin
Immunosuppressants

Chemicals and Materials By Patient Type (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Chemicals and Materials By Disease Type (USD Million, 2025-2035)

Immune Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Apparent Benign Purpura

Chemicals and Materials By Administration Route (USD Million, 2025-2035)

Intravenous
Oral
Subcutaneous

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”